{
    "nct_id": "NCT06411691",
    "official_title": "Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Adenocarcinoma",
    "inclusion_criteria": "* Age â‰¥18 years.\n* Have histologically or cytologically - proven cancer of the pancreas or colon.\n* Have tumor lesions amenable to repeated biopsy, and patient's acceptance to have a tumor biopsy of an accessible lesion at baseline and on treatment if the lesion can be biopsied with acceptable clinical risk (as judged by the investigator).\n* Measurable disease as per RECIST 1.1.\n* Have sufficient and accessible tissue for next generation sequencing (NGS) and immune-phenotyping.\n* Have one of the KRAS mutations included in the vaccine at the time of vaccination expressed in tumor.\n* Cohort A: Have received 4-6 months of FOLFIRINOX or gemcitabine+nab-paclitaxel for the 1st line treatment of metastatic unresectable PDAC.\n* Cohort B: Have received 4-6 months of 1st line SOC chemotherapy per NCCN guidelines (FOLFIRINOX, FOLFOX, FOLFIRI +/- targeted therapy with VEGFi or EGFRi) of metastatic CRC.\n* Cohort C: Have received no more than 3 lines of systemic chemotherapy, including prior KRAS inhibitor.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0.\n* Life expectancy of greater than 3 months.\n* Patients must have adequate organ and marrow function defined by study-specified laboratory tests prior to initial study drug.\n* Woman of childbearing potential must have a negative pregnancy test and follow contraceptive guidelines as defined per protocol.\n* Men must use acceptable form of birth control while on study.\n* Ability to understand and willingness to sign a written informed consent document.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Is a candidate for definitive surgical resection.\n* Known history or evidence of brain metastases and/or leptomeningeal spread.\n* Prior treatment with immunotherapy agents (including, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA4, etc.).\n* Receiving active immunosuppressive agents or chronic use of systemic corticosteroids within 14 days of vaccine treatment.\n* Has active autoimmune disease that has required systemic treatment in the past 5 years, or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents.\n* Known history or concurrent interstitial lung disease.\n* Has a pulse oximetry < 95% on room air.\n* Requires the use of home oxygen.\n* Infection with HIV or hepatitis B or C.\n* Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, metastatic cancer, or psychiatric illness/social situations that would limit compliance with study requirements.\n* Has been diagnosed with another cancer or myeloproliferative disorder in the past 5 years except for superficial bladder cancer, non-melanoma skin cancers, DCIS, a low-grade prostate cancer, or a cancer not expected to impact life expectancy and not requiring therapy.\n* Has had surgery within 28 days of dosing of investigational agent, excluding minor procedures (dental work, skin biopsy, etc.), celiac plexus block, and biliary stent placement.\n* Has received any non-oncology live vaccine therapy used for prevention of infectious diseases within 28 days of study treatment.\n* If at the time of signing informed consent, a regular user (including \"recreational use\") of any illicit drugs or other substance abuse (including alcohol) that could potentially interfere with adherence to study procedures or requirements.\n* Any other sound medical, psychiatric, and/or social reason as determined by the Investigator.\n* Unwilling or unable to follow the study schedule for any reason.\n* Are pregnant or breastfeeding.\n* Any radiological or clinical pleural effusions or ascites.\n* History of malignant small bowel obstruction.\n* On parenteral nutrition.\n* Known or suspected hypersensitivity to Hiltonol.",
    "miscellaneous_criteria": ""
}